ABOUT THE EXPERT
William K. Oh,
Chief, Division of Hematology and Medical Oncology
Deputy Director, The Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, NY
William K. Oh, MD, is the chief of the Division of Hematology and Medical Oncology; professor of medicine, hematology, medical oncology, and urology; and the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine. Dr Oh is also the associate director for clinical research at The Tisch Cancer Institute.
His clinical interests include management of genitourinary malignancies (prostate, renal, bladder, adrenocortical and testicular cancers). His research nterests include exploring the role of chemotherapy in both castration-resistant prostate cancer and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, he is assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. He also studies the role of secondary hormone therapies in the treatment of advanced prostate cancer.
Another major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr Oh’s recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (eg, nilutamide, ketoconazole, vinorelbine, docetaxel, and mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.